AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 51 min read$CORT

Maduck Sean sold $2.3M of CORT

Maduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 5, 2026, 9:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size, price, and post-transaction holdings. This typically informs sentiment but rarely changes fundamentals.

02

Market read

Traders may briefly reassess sentiment around CORT due to insider selling, but the 10b5-1 structure makes it less likely to drive a sustained repricing.

03

What to watch

The article does not provide broader insider activity history, total insider ownership changes over time, or whether other executives sold/bought around the same period.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by an officer and explicitly tied to a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics Form 4 shows officer Maduck Sean sold 20,305 shares at $114.7045 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted because the sale is pre-arranged under Rule 10b5-1.

Evidence & confidence

The filing is a primary-source Form 4 with a specified sale price, size, and explicit 10b5-1 pre-arrangement, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single routine 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can still coincide with private views on valuation or liquidity needs, so some traders may treat it as a mild negative signal.

Key entities

  • issuer
    Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure (CORT).

  • insider
    Maduck Sean

    Officer who sold 20,305 shares under a Rule 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 31
$CORTMed

Corcept Therapeutics Q2 Earnings Call Highlights

Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff.

yahoo.com6 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 30
$METAMed

Futures Rise As Oil Drops, Bond Selling Slows, Meta Tumbles And Microsoft Soars

US stock index futures rose in premarket after a prior selloff tied to Fed-related concerns. Microsoft shares jumped about 9% after cloud growth accelerated, while Meta fell about 8% after revenue guidance disappointed and free cash flow was weak. Bond selling slowed and 30-year yields hit a two-decade high near 5.22%. Several other earnings moves were reported, including MO, CVNA, CMG, and QCOM.

zerohedge.com7 min